Samsung Bioepis said on the 2nd that it will directly sell the bone disease treatments "Obodense" and "Xbryk" in Europe. Obodense will be sold starting this month, and Xbryk from Jan. next year.
Obodense and Xbryk are biosimilars of "Prolia" and "Xgeva," developed by the global drugmaker Amgen. They contain denosumab and are classified, depending on dose and dosing interval, as an osteoporosis treatment (Obodense) and a treatment for giant cell tumor of bone and other conditions (Xbryk).
The company said, "With this, we have commercialized a total of 10 products in the European market over 10 years and expanded our portfolio across disease areas in immunology, oncology, ophthalmology and hematology."
Samsung Bioepis entered Europe in 2016 by launching "Benepali (ingredient name etanercept)," a biosimilar of the autoimmune disease treatment "Enbrel." The only directly sold product had been "Episklee (ingredient name eculizumab)," a biosimilar of the rare disease treatment "Soliris."
Linda Choi, executive vice president and head of commercial at Samsung Bioepis, said, "Based on our know-how in developing and selling biosimilars across diverse therapeutic areas in the global market, we are launching Obodense and Xbryk," adding, "We will continue efforts to provide patients with more treatment opportunities through biosimilars and to enhance social value by reducing health insurance expenditures."